Pulmatrix Inc.
Changing medicine with a new generation of pulmonary-delivered therapeutics
Changing medicine with a new generation of pulmonary-delivered therapeutics
**Pulmatrix Inc.** is dedicated to revolutionizing medicine through the development and commercialization of innovative therapeutics globally. With the proprietary iSPERSE™ technology, the company aims to optimize the delivery of respiratory and non-respiratory therapies through the respiratory system. Founded in **2003**, Pulmatrix operates within the **Biotechnology, Health and Wellness, and Pharmaceutical** industries. The latest milestone for the company was a **Post-IPO Equity investment** on **17 December 2021**. The specific investors in this round were not disclosed. Pulmatrix's slogan, "Changing medicine with a new generation of pulmonary-delivered therapeutics," encapsulates its commitment to pioneering medical advancements through advanced delivery mechanisms.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | Unknown | - | 17 Dec 2021 | |
| Post-IPO Equity | Unknown | - | 11 Feb 2021 | |
| Post-IPO Equity | Unknown | - | 08 Apr 2019 | |
| Grant | Unknown | - | 01 Oct 2015 | |
| Post-IPO Equity | Unknown | - | 16 Jun 2015 |
No recent news or press coverage available for Pulmatrix Inc..
We care about your data, and we'd love to use cookies make your experience better.
